首页 > 最新文献

Open Respiratory Medicine Journal最新文献

英文 中文
Low Doses of Kretek Cigarette Smoke Altered Rat Lung Histometric, and Overexpression of the p53 Gene. 低剂量的 Kretek 卷烟烟雾改变了大鼠肺组织计量学和 p53 基因的过度表达。
Q3 Medicine Pub Date : 2024-04-26 eCollection Date: 2024-01-01 DOI: 10.2174/0118743064285619240327055359
Edy Parwanto, David Tjahyadi, Sisca Sisca, Husnun Amalia, Nany Hairunisa, Hosea Jaya Edy, Ashaolu Victoria Oladimeji, Noureddine Djebli

Background: The components of kretek cigarettes include tobacco as the main part, clove, and sauce. Filtered kretek cigarettes are kretek cigarettes that have one end filtered. Cigarette smoke contributes to the disruption of the respiratory system, so it is necessary to know the effect of low doses of cigarette smoke on changes in the histometric of the respiratory system, and whether it affects p53 gene expression. This study aims to determine changes in the histometric of the respiratory system and p53 gene expression.

Methods: In this study, we used Sprague-Dawley rats. Group I of rats breathing normal air, were not exposed to filtered kretek cigarette smoke (as a control). Group II of rats, as a treatment group, were exposed to filtered kretek cigarette smoke 1 stick/day for 3 months. The results of lung histometry measurements and p53 gene expression between groups were analyzed using the Independent Sample T-test. The difference between groups is significant if the test results show P < 0.05.

Results: Bronchioles length, width, area, and perimeter in group I were 40.55±1.57 μm, 14.82±0.41 μm, 494.61±5.62 μm2, and 233.87±4.51 μm, respectively. Bronchioles length, width, area, and perimeter in group II were 30.76±0.78 μm, 9.28±0.40 μm, 297.32±2.53 μm2, and 177.84±5.15 μm, respectively. The area and perimeter of respiratory bronchioles in group I were 17.68±0.49 μm2, and 26.60±0.52 μm respectively, while those in group II were 19.28±0.35 μm2, and 29.28±0.35 μm, respectively. Mucus was found in the bronchioles and respiratory bronchioles in group II, however, there was no visible mucus observed in group I. In addition, it was also concluded that exposure to low doses of filtered kretek cigarette smoke, 1 cigarette/day for 3 months, increased the expression of the p53 gene in the lungs of rats.

Conclusion: The size of bronchioles in rats decreased after being exposed to filtered kretek cigarette smoke 1 stick/day for 3 months, while the size of respiratory bronchioles increased. In addition, exposure to filtered kretek cigarette smoke increased the expression of the p53 gene in the rat lungs.

背景:克雷泰香烟的成分包括主要成分烟草、丁香和酱料。过滤嘴克雷泰香烟是一端经过过滤的克雷泰香烟。香烟烟雾会导致呼吸系统紊乱,因此有必要了解低剂量香烟烟雾对呼吸系统组织测量变化的影响,以及是否会影响 p53 基因的表达。本研究旨在确定呼吸系统组织测量和 p53 基因表达的变化:本研究使用 Sprague-Dawley 大鼠。I 组大鼠呼吸正常空气,不接触过滤克雷泰香烟烟雾(作为对照)。II 组大鼠作为治疗组,每天接触 1 支过滤嘴克雷泰香烟烟雾,持续 3 个月。采用独立样本 T 检验分析组间肺组织测量和 p53 基因表达的结果。如果检验结果显示 P < 0.05,则组间差异具有显著性:I组支气管长、宽、面积和周长分别为40.55±1.57 μm、14.82±0.41 μm、494.61±5.62 μm2和233.87±4.51 μm。Ⅱ组支气管长、宽、面积和周长分别为(30.76±0.78)μm、(9.28±0.40)μm、(297.32±2.53)μm2 和(177.84±5.15)μm。I 组呼吸支气管的面积和周长分别为(17.68±0.49)μm2 和(26.60±0.52)μm,II 组分别为(19.28±0.35)μm2 和(29.28±0.35)μm。此外,研究还得出结论,接触低剂量过滤克雷泰香烟烟雾(1 支/天,持续 3 个月)会增加大鼠肺部 p53 基因的表达:结论:在连续 3 个月每天吸 1 支过滤嘴克雷泰香烟后,大鼠支气管的体积减小,而呼吸支气管的体积增大。此外,接触过滤嘴克雷泰香烟烟雾会增加大鼠肺中 p53 基因的表达。
{"title":"Low Doses of Kretek Cigarette Smoke Altered Rat Lung Histometric, and Overexpression of the p53 Gene.","authors":"Edy Parwanto, David Tjahyadi, Sisca Sisca, Husnun Amalia, Nany Hairunisa, Hosea Jaya Edy, Ashaolu Victoria Oladimeji, Noureddine Djebli","doi":"10.2174/0118743064285619240327055359","DOIUrl":"10.2174/0118743064285619240327055359","url":null,"abstract":"<p><strong>Background: </strong>The components of kretek cigarettes include tobacco as the main part, clove, and sauce. Filtered kretek cigarettes are kretek cigarettes that have one end filtered. Cigarette smoke contributes to the disruption of the respiratory system, so it is necessary to know the effect of low doses of cigarette smoke on changes in the histometric of the respiratory system, and whether it affects p53 gene expression. This study aims to determine changes in the histometric of the respiratory system and p53 gene expression.</p><p><strong>Methods: </strong>In this study, we used Sprague-Dawley rats. Group I of rats breathing normal air, were not exposed to filtered kretek cigarette smoke (as a control). Group II of rats, as a treatment group, were exposed to filtered kretek cigarette smoke 1 stick/day for 3 months. The results of lung histometry measurements and p53 gene expression between groups were analyzed using the Independent Sample T-test. The difference between groups is significant if the test results show P < 0.05.</p><p><strong>Results: </strong>Bronchioles length, width, area, and perimeter in group I were 40.55±1.57 μm, 14.82±0.41 μm, 494.61±5.62 μm<sup>2</sup>, and 233.87±4.51 μm, respectively. Bronchioles length, width, area, and perimeter in group II were 30.76±0.78 μm, 9.28±0.40 μm, 297.32±2.53 μm<sup>2</sup>, and 177.84±5.15 μm, respectively. The area and perimeter of respiratory bronchioles in group I were 17.68±0.49 μm<sup>2</sup>, and 26.60±0.52 μm respectively, while those in group II were 19.28±0.35 μm<sup>2</sup>, and 29.28±0.35 μm, respectively. Mucus was found in the bronchioles and respiratory bronchioles in group II, however, there was no visible mucus observed in group I. In addition, it was also concluded that exposure to low doses of filtered kretek cigarette smoke, 1 cigarette/day for 3 months, increased the expression of the p53 gene in the lungs of rats.</p><p><strong>Conclusion: </strong>The size of bronchioles in rats decreased after being exposed to filtered kretek cigarette smoke 1 stick/day for 3 months, while the size of respiratory bronchioles increased. In addition, exposure to filtered kretek cigarette smoke increased the expression of the p53 gene in the rat lungs.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"18 ","pages":"e18743064285619"},"PeriodicalIF":0.0,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11311747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Pulse of AI: Implementation of Artificial Intelligence in Healthcare and its Potential Hazards. 人工智能的脉搏:人工智能在医疗保健领域的应用及其潜在危害》(The Pulse of AI: Implementation of Artificial Intelligence in Healthcare and its Potential Hazards)。
Q3 Medicine Pub Date : 2024-01-19 eCollection Date: 2024-01-01 DOI: 10.2174/0118743064289936240115105057
Syeda Farheen Zaidi, Asim Shaikh, Salim Surani

In this editorial, we explore the existing utilization of artificial intelligence (AI) within the healthcare industry, examining both its scope and potential harms if implemented and relied upon on a broader scale. Collaboration among corporations, government bodies, policymakers, and medical experts is essential to address potential concerns, ensuring smooth AI integration into healthcare systems.

在这篇社论中,我们探讨了人工智能(AI)在医疗保健行业中的现有应用,研究了其应用范围以及在更大范围内实施和依赖人工智能可能带来的危害。企业、政府机构、政策制定者和医学专家之间的合作对于解决潜在问题、确保人工智能顺利融入医疗系统至关重要。
{"title":"The Pulse of AI: Implementation of Artificial Intelligence in Healthcare and its Potential Hazards.","authors":"Syeda Farheen Zaidi, Asim Shaikh, Salim Surani","doi":"10.2174/0118743064289936240115105057","DOIUrl":"https://doi.org/10.2174/0118743064289936240115105057","url":null,"abstract":"<p><p>In this editorial, we explore the existing utilization of artificial intelligence (AI) within the healthcare industry, examining both its scope and potential harms if implemented and relied upon on a broader scale. Collaboration among corporations, government bodies, policymakers, and medical experts is essential to address potential concerns, ensuring smooth AI integration into healthcare systems.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"18 ","pages":"e18743064289936"},"PeriodicalIF":0.0,"publicationDate":"2024-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11037519/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140853990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines Reviewed. 慢性阻塞性肺病全球倡议 (GOLD) 2023 指南》已审查。
Q3 Medicine Pub Date : 2024-01-10 eCollection Date: 2024-01-01 DOI: 10.2174/0118743064279064231227070344
Munish Sharma, Sushil Joshi, Prakash Banjade, Shekhar A Ghamande, Salim Surani

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) report is an essential resource for all clinicians who strive to provide optimal care to patients with chronic obstructive lung disease (COPD). The annual report of GOLD makes few revisions and updates besides including data from the preceding year. At an interval, GOLD comes up with a significant modification in its guidelines, which is generally a major overhaul of the pre-existing guidelines. According to the latest 2023 updates, published in November 2022, there have been significant advancements made in the field of COPD. These include the development of more precise definitions for COPD and its exacerbations, the introduction of a new set of parameters to measure exacerbation severity, and updating the COPD assessment tool. Additionally, revisions have been made to the initial and follow-up treatment guidelines. The report also simplifies the treatment algorithm and sheds light on new findings that suggest the use of pharmacological triple therapy can reduce mortality rates. Furthermore, the report includes discussions on inhaler device selection and adherence to COPD medications. These improvements demonstrate a continued effort to enhance COPD treatment and management. Although there are some areas that could benefit from more detailed guidance and explanation, such as the proper utilization of blood eosinophil counts for treatment decisions, and the establishment of treatment protocols post-hospitalization, the latest modifications to the GOLD recommendations will undoubtedly aid healthcare providers in addressing any gaps in patient care. We aim to highlight key changes in the GOLD 2023 report and present a viewpoint about their potential implications in a real-world clinical scenario.

慢性阻塞性肺病全球倡议(GOLD)报告是所有努力为慢性阻塞性肺病(COPD)患者提供最佳治疗的临床医生的重要资源。GOLD 年度报告除了收录前一年的数据外,很少进行修订和更新。每隔一段时间,GOLD 都会对其指南进行重大修改,通常是对原有指南的一次大修。根据 2022 年 11 月发布的最新 2023 年更新版,慢性阻塞性肺病领域取得了重大进展。其中包括为慢性阻塞性肺病及其加重制定了更精确的定义,引入了一套新的参数来衡量加重的严重程度,并更新了慢性阻塞性肺病评估工具。此外,还对初始和后续治疗指南进行了修订。报告还简化了治疗算法,并阐明了新的研究结果,即使用药物三联疗法可降低死亡率。此外,报告还讨论了吸入器的选择和慢性阻塞性肺病药物治疗的依从性。这些改进表明,人们一直在努力加强慢性阻塞性肺病的治疗和管理。尽管在某些方面还需要更详细的指导和解释,如在治疗决策中正确使用血液嗜酸性粒细胞计数和建立入院后治疗方案,但 GOLD 建议的最新修改无疑将有助于医疗服务提供者弥补患者护理中的不足。我们旨在强调 GOLD 2023 报告中的主要变化,并就其在实际临床场景中的潜在影响发表观点。
{"title":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines Reviewed.","authors":"Munish Sharma, Sushil Joshi, Prakash Banjade, Shekhar A Ghamande, Salim Surani","doi":"10.2174/0118743064279064231227070344","DOIUrl":"https://doi.org/10.2174/0118743064279064231227070344","url":null,"abstract":"<p><p>The Global Initiative for Chronic Obstructive Lung Disease (GOLD) report is an essential resource for all clinicians who strive to provide optimal care to patients with chronic obstructive lung disease (COPD). The annual report of GOLD makes few revisions and updates besides including data from the preceding year. At an interval, GOLD comes up with a significant modification in its guidelines, which is generally a major overhaul of the pre-existing guidelines. According to the latest 2023 updates, published in November 2022, there have been significant advancements made in the field of COPD. These include the development of more precise definitions for COPD and its exacerbations, the introduction of a new set of parameters to measure exacerbation severity, and updating the COPD assessment tool. Additionally, revisions have been made to the initial and follow-up treatment guidelines. The report also simplifies the treatment algorithm and sheds light on new findings that suggest the use of pharmacological triple therapy can reduce mortality rates. Furthermore, the report includes discussions on inhaler device selection and adherence to COPD medications. These improvements demonstrate a continued effort to enhance COPD treatment and management. Although there are some areas that could benefit from more detailed guidance and explanation, such as the proper utilization of blood eosinophil counts for treatment decisions, and the establishment of treatment protocols post-hospitalization, the latest modifications to the GOLD recommendations will undoubtedly aid healthcare providers in addressing any gaps in patient care. We aim to highlight key changes in the GOLD 2023 report and present a viewpoint about their potential implications in a real-world clinical scenario.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"18 ","pages":"e18743064279064"},"PeriodicalIF":0.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11037508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140855390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of Interleukin-4 Receptor α Chain I50V Gene Variant (rs1805010) and Asthma in Iranian Population: A Case-control Study. 伊朗人口中白细胞介素-4 受体 α 链 I50V 基因变异(rs1805010)与哮喘的关系:一项病例对照研究。
Q3 Medicine Pub Date : 2024-01-10 eCollection Date: 2024-01-01 DOI: 10.2174/0118743064266613231123103523
Masouma Mowahedi, Azam Aramesh, Mozhgan Sorkhi Khouzani, Marjan Sorkhi Khouzani, Saeed Daryanoush, Mohammad Samet, Morteza Samadi

Background: Asthma is one of the respiratory disorders caused by chronic airway inflammation. IL-4 has been identified as one of the participating interleukins in the severity of asthma.

Objective: A case-control study was conducted to determine the association of rs1805010, a single nucleotide polymorphism in the interleukin 4 receptor α chain, with asthma and immunoglobulin E and IL-17A serum levels in Iranian populations.

Methods: ELISA was used to investigate the relationship between three different varieties of SNP I50V and serum IL-17A levels, as well as total IgE levels. Based on GINA criteria, patients were classified into mild, moderate, and severe groups based on the association between SNP I50V, IL-17A, and total IgE. In order to analyze the data, the student-t-test and the one-way ANOVA were used.

Results: The SNP I50V was associated with asthma in a significant way (p = 0.001). IL-17A and total IgE levels were significantly higher in asthmatic patients than in control participants (p 0.05 and p 0.021, respectively), but neither showed any association with SNP I50V in the asthmatic patients.

Conclusion: Asthma patients have a higher prevalence of the I allele, reflecting the significance of Th2 cells. Although total IgE and IL-17A levels increased in both disease subgroups, total IgE level augmentation correlates directly with disease severity, while IL-17A level enhancement does not.

背景:哮喘是由慢性气道炎症引起的呼吸系统疾病之一。IL-4 已被确定为参与哮喘严重程度的白细胞介素之一:目的:通过病例对照研究确定 rs1805010(白细胞介素 4 受体 α 链中的单核苷酸多态性)与伊朗人群哮喘、免疫球蛋白 E 和 IL-17A 血清水平的关系:采用酶联免疫吸附法研究三种不同的 SNP I50V 与血清 IL-17A 水平以及总 IgE 水平之间的关系。根据 GINA 标准,按照 SNP I50V、IL-17A 和总 IgE 之间的关系将患者分为轻度、中度和重度组。数据分析采用了student-t检验和单因素方差分析:结果:SNP I50V与哮喘有显著相关性(p = 0.001)。哮喘患者的 IL-17A 和总 IgE 水平明显高于对照组参与者(分别为 p 0.05 和 p 0.021),但两者均与哮喘患者的 SNP I50V 无关:结论:哮喘患者等位基因 I 的发生率较高,反映了 Th2 细胞的重要性。尽管两个疾病亚组的总 IgE 和 IL-17A 水平都有所升高,但总 IgE 水平的升高与疾病的严重程度直接相关,而 IL-17A 水平的升高与疾病的严重程度无关。
{"title":"Association of Interleukin-4 Receptor α Chain I50V Gene Variant (rs1805010) and Asthma in Iranian Population: A Case-control Study.","authors":"Masouma Mowahedi, Azam Aramesh, Mozhgan Sorkhi Khouzani, Marjan Sorkhi Khouzani, Saeed Daryanoush, Mohammad Samet, Morteza Samadi","doi":"10.2174/0118743064266613231123103523","DOIUrl":"https://doi.org/10.2174/0118743064266613231123103523","url":null,"abstract":"<p><strong>Background: </strong>Asthma is one of the respiratory disorders caused by chronic airway inflammation. IL-4 has been identified as one of the participating interleukins in the severity of asthma.</p><p><strong>Objective: </strong>A case-control study was conducted to determine the association of rs1805010, a single nucleotide polymorphism in the interleukin 4 receptor α chain, with asthma and immunoglobulin E and IL-17A serum levels in Iranian populations.</p><p><strong>Methods: </strong>ELISA was used to investigate the relationship between three different varieties of SNP I50V and serum IL-17A levels, as well as total IgE levels. Based on GINA criteria, patients were classified into mild, moderate, and severe groups based on the association between SNP I50V, IL-17A, and total IgE. In order to analyze the data, the student-t-test and the one-way ANOVA were used.</p><p><strong>Results: </strong>The SNP I50V was associated with asthma in a significant way (p = 0.001). IL-17A and total IgE levels were significantly higher in asthmatic patients than in control participants (p 0.05 and p 0.021, respectively), but neither showed any association with SNP I50V in the asthmatic patients.</p><p><strong>Conclusion: </strong>Asthma patients have a higher prevalence of the I allele, reflecting the significance of Th2 cells. Although total IgE and IL-17A levels increased in both disease subgroups, total IgE level augmentation correlates directly with disease severity, while IL-17A level enhancement does not.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"18 ","pages":"e18743064266613"},"PeriodicalIF":0.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11037512/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updates on British Thoracic Society Statement on Pleural Disease and Procedures 2023. 英国胸科学会关于胸膜疾病和 2023 年程序声明的更新。
Q3 Medicine Pub Date : 2023-12-01 eCollection Date: 2023-01-01 DOI: 10.2174/0118743064286775231128104253
Ashish Subedi, Prakash Banjade, Sushil Joshi, Munish Sharma, Salim Surani
{"title":"Updates on British Thoracic Society Statement on Pleural Disease and Procedures 2023.","authors":"Ashish Subedi, Prakash Banjade, Sushil Joshi, Munish Sharma, Salim Surani","doi":"10.2174/0118743064286775231128104253","DOIUrl":"https://doi.org/10.2174/0118743064286775231128104253","url":null,"abstract":"","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"17 ","pages":"e18743064286775"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11037506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140860873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radial Endobronchial Ultrasound-guided Transbronchial Cryobiopsy versus Forceps Biopsy for the Diagnosis of Solitary Pulmonary Nodules: A Prospective Randomised Trial 桡骨支气管超声引导下经支气管低温活检与钳活检诊断孤立性肺结节:一项前瞻性随机试验
Q3 Medicine Pub Date : 2023-10-10 DOI: 10.2174/0118743064262132230922110818
Michael Brown, Phan Nguyen, Hubertus Jersmann, Mark Holmes, Michelle Wong
Background: Improvements in pulmonary diagnostic imaging and the development of lung cancer screening are increasing the prevalence of Solitary pulmonary nodules (SPNs). Fluoroscopically guided radial endobronchial ultrasound (EBUS) with transbronchial forceps biopsy (TB-FB) has been the conventional diagnostic method. Transbronchial cryobiopsy (TB-CB) is an alternative biopsy method. We sought to compare transbronchial cryobiopsy to transbronchial forceps biopsy for the diagnosis of SPNs. Methods: A prospective, single-centre, randomised controlled trial was conducted at the Royal Adelaide Hospital (RAH). Patients with SPNs were randomised to either 5 transbronchial forceps biopsies or one transbronchial cryobiopsy. Complete blinding of investigators and participants was not possible, as transbronchial cryobiopsy required general anaesthesia. The primary outcome was diagnostic yield with secondary outcomes of specimen size, diagnostic yield for subsets challenging to access with forceps and safety. Results: The overall diagnostic yield for the 28 enrolled subjects was 76.8%(22/28). The diagnostic yield was 91.7% (11/12 patients) for transbronchial cryobiopsy and 68.8% (11/16 patients) for forceps biopsy (p=0.14). Median biopsy sizes were consistently larger for the cryobiopsy arm at 7.0mm compared to 2.5mm(p<0.0001). An eccentric EBUS image signalling the probe was adjacent to the nodule occurred in 4/28 cases, and TB-CB confirmed a diagnosis in 3/3 randomised to this arm. There were no major complications with either technique. Conclusion: Transbronchial cryobiopsy under the guidance of fluoroscopy and radial EBUS facilitates larger biopsy specimens without a significant increase in major complications. Further research is required to confirm the effect on diagnostic yield; however, our study supports a role for TB-CB in the diagnosis of SPNs and small, nodule-adjacent biopsies. Clinical Trial Registration Number: Reference number of R20160213(HREC/16/RAH/37).
背景:肺部诊断影像学的改善和肺癌筛查的发展正在增加孤立性肺结节(SPNs)的患病率。透视引导下桡骨支气管超声(EBUS)与经支气管钳活检(TB-FB)一直是常规的诊断方法。经支气管低温活检(TB-CB)是另一种活检方法。我们试图比较经支气管冷冻活检和经支气管钳活检对SPNs的诊断。方法:在阿德莱德皇家医院(RAH)进行了一项前瞻性、单中心、随机对照试验。spn患者随机分为5次经支气管钳活检或1次经支气管冷冻活检。研究者和参与者不可能完全盲化,因为经支气管冷冻活检需要全身麻醉。主要结局是诊断的产出率,次要结局是标本的大小,难以使用镊子和安全的亚群的诊断的产出率。结果:28例入组患者的总诊断率为76.8%(22/28)。经支气管冷冻活检的诊断率为91.7%(11/12例),钳活检的诊断率为68.8%(11/16例)(p=0.14)。冷冻活检臂的中位活检尺寸始终大于2.5mm,为7.0mm (p<0.0001)。在4/28的病例中出现了偏心的EBUS图像,表明探针位于结节附近,该组随机分组的3/3的患者确诊为TB-CB。两种技术均无重大并发症。结论:在透视和桡骨EBUS指导下经支气管冷冻活检可使活检标本更大,且主要并发症明显增加。需要进一步的研究来确认对诊断率的影响;然而,我们的研究支持TB-CB在诊断spn和小结节邻近活检中的作用。临床试验注册号:参考号R20160213(HREC/16/RAH/37)。
{"title":"Radial Endobronchial Ultrasound-guided Transbronchial Cryobiopsy versus Forceps Biopsy for the Diagnosis of Solitary Pulmonary Nodules: A Prospective Randomised Trial","authors":"Michael Brown, Phan Nguyen, Hubertus Jersmann, Mark Holmes, Michelle Wong","doi":"10.2174/0118743064262132230922110818","DOIUrl":"https://doi.org/10.2174/0118743064262132230922110818","url":null,"abstract":"Background: Improvements in pulmonary diagnostic imaging and the development of lung cancer screening are increasing the prevalence of Solitary pulmonary nodules (SPNs). Fluoroscopically guided radial endobronchial ultrasound (EBUS) with transbronchial forceps biopsy (TB-FB) has been the conventional diagnostic method. Transbronchial cryobiopsy (TB-CB) is an alternative biopsy method. We sought to compare transbronchial cryobiopsy to transbronchial forceps biopsy for the diagnosis of SPNs. Methods: A prospective, single-centre, randomised controlled trial was conducted at the Royal Adelaide Hospital (RAH). Patients with SPNs were randomised to either 5 transbronchial forceps biopsies or one transbronchial cryobiopsy. Complete blinding of investigators and participants was not possible, as transbronchial cryobiopsy required general anaesthesia. The primary outcome was diagnostic yield with secondary outcomes of specimen size, diagnostic yield for subsets challenging to access with forceps and safety. Results: The overall diagnostic yield for the 28 enrolled subjects was 76.8%(22/28). The diagnostic yield was 91.7% (11/12 patients) for transbronchial cryobiopsy and 68.8% (11/16 patients) for forceps biopsy (p=0.14). Median biopsy sizes were consistently larger for the cryobiopsy arm at 7.0mm compared to 2.5mm(p<0.0001). An eccentric EBUS image signalling the probe was adjacent to the nodule occurred in 4/28 cases, and TB-CB confirmed a diagnosis in 3/3 randomised to this arm. There were no major complications with either technique. Conclusion: Transbronchial cryobiopsy under the guidance of fluoroscopy and radial EBUS facilitates larger biopsy specimens without a significant increase in major complications. Further research is required to confirm the effect on diagnostic yield; however, our study supports a role for TB-CB in the diagnosis of SPNs and small, nodule-adjacent biopsies. Clinical Trial Registration Number: Reference number of R20160213(HREC/16/RAH/37).","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136360533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Bioinformatic Algorithm based on Pulmonary Endoarterial Biopsy for Targeted Pulmonary Arterial Hypertension Therapy 基于肺动脉活检的生物信息学算法在肺动脉高压靶向治疗中的应用
Q3 Medicine Pub Date : 2023-10-04 DOI: 10.2174/18743064-v17-230927-2023-9
Abraham Rothman, David Mann, Jose A. Nunez, Reinhardt Tarmidi, Humberto Restrepo, Valeri Sarukhanov, Roy Williams, William N. Evans
Background: Optimal pharmacological therapy for pulmonary arterial hypertension (PAH) remains unclear, as pathophysiological heterogeneity may affect therapeutic outcomes. A ranking methodology based on pulmonary vascular genetic expression analysis could assist in medication selection and potentially lead to improved prognosis. Objective: To describe a bioinformatics approach for ranking currently approved pulmonary arterial antihypertensive agents based on gene expression data derived from percutaneous endoarterial biopsies in an animal model of pulmonary hypertension. Methods: We created a chronic PAH model in Micro Yucatan female swine by surgical anastomosis of the left pulmonary artery to the descending aorta. A baseline catheterization, angiography and pulmonary endoarterial biopsy were performed. We obtained pulmonary vascular biopsy samples by passing a biopsy catheter through a long 8 French sheath, introduced via the carotid artery, into 2- to 3-mm peripheral pulmonary arteries. Serial procedures were performed on days 7, 21, 60, and 180 after surgical anastomosis. RNA microarray studies were performed on the biopsy samples. Results: Utilizing the medical literature, we developed a list of PAH therapeutic agents, along with a tabulation of genes affected by these agents. The effect on gene expression from pharmacogenomic interactions was used to rank PAH medications at each time point. The ranking process allowed the identification of a theoretical optimum three-medication regimen. Conclusion: We describe a new potential paradigm in the therapy for PAH, which would include endoarterial biopsy, molecular analysis and tailored pharmacological therapy for patients with PAH.
背景:肺动脉高压(PAH)的最佳药物治疗尚不清楚,因为病理生理异质性可能影响治疗结果。基于肺血管基因表达分析的排序方法有助于药物选择,并有可能改善预后。目的:描述一种生物信息学方法,基于肺动脉高压动物模型经皮动脉内活检获得的基因表达数据,对目前批准的肺动脉降压药进行排名。方法:采用左肺动脉与降主动脉吻合的方法,建立微尤卡坦母猪慢性肺动脉高压模型。进行了基线导管穿刺、血管造影和肺动脉活检。我们通过将活检导管穿过长8法国鞘,经颈动脉插入2至3毫米的外周肺动脉,获得肺血管活检样本。术后第7天、21天、60天和180天进行了一系列手术。对活检样本进行RNA微阵列研究。结果:利用医学文献,我们开发了多环芳烃治疗剂的列表,以及受这些药物影响的基因表。药物基因组相互作用对基因表达的影响用于对每个时间点的多环芳烃药物进行排序。排序过程允许确定理论上最优的三种药物治疗方案。结论:我们描述了一种新的治疗PAH的潜在模式,包括动脉内活检、分子分析和针对PAH患者的量身定制的药物治疗。
{"title":"A Bioinformatic Algorithm based on Pulmonary Endoarterial Biopsy for Targeted Pulmonary Arterial Hypertension Therapy","authors":"Abraham Rothman, David Mann, Jose A. Nunez, Reinhardt Tarmidi, Humberto Restrepo, Valeri Sarukhanov, Roy Williams, William N. Evans","doi":"10.2174/18743064-v17-230927-2023-9","DOIUrl":"https://doi.org/10.2174/18743064-v17-230927-2023-9","url":null,"abstract":"Background: Optimal pharmacological therapy for pulmonary arterial hypertension (PAH) remains unclear, as pathophysiological heterogeneity may affect therapeutic outcomes. A ranking methodology based on pulmonary vascular genetic expression analysis could assist in medication selection and potentially lead to improved prognosis. Objective: To describe a bioinformatics approach for ranking currently approved pulmonary arterial antihypertensive agents based on gene expression data derived from percutaneous endoarterial biopsies in an animal model of pulmonary hypertension. Methods: We created a chronic PAH model in Micro Yucatan female swine by surgical anastomosis of the left pulmonary artery to the descending aorta. A baseline catheterization, angiography and pulmonary endoarterial biopsy were performed. We obtained pulmonary vascular biopsy samples by passing a biopsy catheter through a long 8 French sheath, introduced via the carotid artery, into 2- to 3-mm peripheral pulmonary arteries. Serial procedures were performed on days 7, 21, 60, and 180 after surgical anastomosis. RNA microarray studies were performed on the biopsy samples. Results: Utilizing the medical literature, we developed a list of PAH therapeutic agents, along with a tabulation of genes affected by these agents. The effect on gene expression from pharmacogenomic interactions was used to rank PAH medications at each time point. The ranking process allowed the identification of a theoretical optimum three-medication regimen. Conclusion: We describe a new potential paradigm in the therapy for PAH, which would include endoarterial biopsy, molecular analysis and tailored pharmacological therapy for patients with PAH.","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135647605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Usefulness of High-resolution Computed Tomography for Macrolide Therapy of Idiopathic Bronchiectasis. 高分辨率计算机断层扫描在大环内酯类药物治疗特发性支气管扩张症中的应用。
Q3 Medicine Pub Date : 2023-08-29 eCollection Date: 2023-01-01 DOI: 10.2174/18743064-v17-230822-2022-27
Zenya Saito, Masahiro Yoshida, Shota Uchiyama, Saiko Nishioka, Kentaro Tamura, Nobumasa Tamura

Background: High-resolution computed tomography (HRCT) correlates with clinical symptoms, respiratory function, and quality of life in bronchiectasis.

Objective: We aimed to investigate the relationship between macrolide and acute exacerbation (AE) in idiopathic bronchiectasis classified by the Bronchiectasis Radiologically Indexed CT Score (BRICS).

Methods: We retrospectively reviewed the medical records of patients diagnosed with idiopathic bronchiectasis between April 2014 and December 2020 at a single hospital. Overall, 115 patients with idiopathic bronchiectasis were selected and divided into three groups, according to the BRICS. Each group was divided into subgroups with and without macrolide therapy, and the number of patients with AE in each group was retrospectively compared.

Results: About 45, 48, and 22 patients were included in the mild, moderate, and severe groups, respectively. In the mild group, the subgroup with macrolide therapy had significantly fewer patients with single AE than those without macrolide ( P = 0.029). There was no significant difference in the moderate and severe groups ( P = 1.00 and 0.64, respectively). In the multiple AE, the subgroup with macrolide therapy had significantly fewer patients than those without macrolide therapy in the mild, moderate, and severe groups ( P = 0.024, 0.029, and 0.026, respectively).

Conclusion: HRCT severity assessment might be useful in predicting treatment efficacy in patients with idiopathic bronchiectasis without previous AEs. Further large-scale clinical trials are required on the usefulness of HRCT in the future.

背景:高分辨率计算机断层扫描(HRCT)与支气管扩张症的临床症状、呼吸功能和生活质量相关。目的:我们旨在研究大环内酯类药物与支气管扩张症急性加重期(AE)的关系。方法:回顾性回顾2014年4月至2020年12月在一家医院诊断为特发性支气管扩张症的患者的医疗记录。根据金砖国家,总共选择了115名特发性支气管扩张症患者,并将其分为三组。每组被分为接受和不接受大环内酯类药物治疗的亚组,并对每组AE患者的数量进行回顾性比较。结果:约45、48和22名患者分别被纳入轻度、中度和重度组。在轻度组中,接受大环内酯类药物治疗的亚组发生单一AE的患者明显少于未接受大环环内酯类治疗的患者(P=0.029)。中度组和重度组之间没有显著差异(分别为P=1.00和0.64)。在多发性AE中,在轻度、中度和重度组中,接受大环内酯类药物治疗的亚组患者明显少于未接受大环利类药物治疗组(分别为P=0.024、0.029和0.026)。结论:HRCT严重程度评估可能有助于预测无既往AE的特发性支气管扩张患者的治疗效果。未来还需要对HRCT的有用性进行进一步的大规模临床试验。
{"title":"Usefulness of High-resolution Computed Tomography for Macrolide Therapy of Idiopathic Bronchiectasis.","authors":"Zenya Saito,&nbsp;Masahiro Yoshida,&nbsp;Shota Uchiyama,&nbsp;Saiko Nishioka,&nbsp;Kentaro Tamura,&nbsp;Nobumasa Tamura","doi":"10.2174/18743064-v17-230822-2022-27","DOIUrl":"https://doi.org/10.2174/18743064-v17-230822-2022-27","url":null,"abstract":"<p><strong>Background: </strong>High-resolution computed tomography (HRCT) correlates with clinical symptoms, respiratory function, and quality of life in bronchiectasis.</p><p><strong>Objective: </strong>We aimed to investigate the relationship between macrolide and acute exacerbation (AE) in idiopathic bronchiectasis classified by the Bronchiectasis Radiologically Indexed CT Score (BRICS).</p><p><strong>Methods: </strong>We retrospectively reviewed the medical records of patients diagnosed with idiopathic bronchiectasis between April 2014 and December 2020 at a single hospital. Overall, 115 patients with idiopathic bronchiectasis were selected and divided into three groups, according to the BRICS. Each group was divided into subgroups with and without macrolide therapy, and the number of patients with AE in each group was retrospectively compared.</p><p><strong>Results: </strong>About 45, 48, and 22 patients were included in the mild, moderate, and severe groups, respectively. In the mild group, the subgroup with macrolide therapy had significantly fewer patients with single AE than those without macrolide ( <i>P</i> = 0.029). There was no significant difference in the moderate and severe groups ( <i>P</i> = 1.00 and 0.64, respectively). In the multiple AE, the subgroup with macrolide therapy had significantly fewer patients than those without macrolide therapy in the mild, moderate, and severe groups ( <i>P</i> = 0.024, 0.029, and 0.026, respectively).</p><p><strong>Conclusion: </strong>HRCT severity assessment might be useful in predicting treatment efficacy in patients with idiopathic bronchiectasis without previous AEs. Further large-scale clinical trials are required on the usefulness of HRCT in the future.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"17 ","pages":"e187430642307250"},"PeriodicalIF":0.0,"publicationDate":"2023-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71427651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis and Management of Patients with Connective Tissue Disease-related Fibrosing Interstitial Lung Diseases. 结缔组织疾病相关纤维化间质性肺疾病患者的诊断和治疗。
Q3 Medicine Pub Date : 2023-08-15 eCollection Date: 2023-01-01 DOI: 10.2174/18743064-v17-e230714-2022-26
Bonnie Wang, Vivek Nagaraja

Background: Fibrotic interstitial lung disease is an important driver of morbidity and mortality in patients with connective tissue diseases (CTD). Due to the lack of prospective randomized trial data in this population, practice pattern variation exists in the management of patients with CTD.

Case presentation: This case series describes three patients, each with a different background of autoimmunity complicated by fibrotic interstitial lung disease (ILD). We review their initial presentations, follow their disease trajectories on currently available treatments, and reference forthcoming clinical trials.

Conclusion: Clinical impact or potential implications. Response to immunosuppression and antifibrotic therapy is variable in patients with connective tissue disease-related fibrosing interstitial lung disease. Data from prospective clinical trials and longitudinal registry studies will conceivably provide additional insight into improving care for these patients.

背景:纤维间质性肺病是结缔组织疾病(CTD)患者发病率和死亡率的重要驱动因素。由于缺乏该人群的前瞻性随机试验数据,CTD患者的管理存在实践模式差异。病例介绍:本病例系列描述了三名患者,每个患者都有不同的自身免疫背景,并伴有纤维间质性肺病(ILD)。我们回顾了他们的初步陈述,跟踪了他们目前可用治疗方法的疾病轨迹,并参考了即将进行的临床试验。结论:临床影响或潜在影响。结缔组织疾病相关纤维化间质性肺病患者对免疫抑制和抗纤维化治疗的反应是可变的。来自前瞻性临床试验和纵向注册研究的数据将为改善这些患者的护理提供更多的见解。
{"title":"Diagnosis and Management of Patients with Connective Tissue Disease-related Fibrosing Interstitial Lung Diseases.","authors":"Bonnie Wang,&nbsp;Vivek Nagaraja","doi":"10.2174/18743064-v17-e230714-2022-26","DOIUrl":"https://doi.org/10.2174/18743064-v17-e230714-2022-26","url":null,"abstract":"<p><strong>Background: </strong>Fibrotic interstitial lung disease is an important driver of morbidity and mortality in patients with connective tissue diseases (CTD). Due to the lack of prospective randomized trial data in this population, practice pattern variation exists in the management of patients with CTD.</p><p><strong>Case presentation: </strong>This case series describes three patients, each with a different background of autoimmunity complicated by fibrotic interstitial lung disease (ILD). We review their initial presentations, follow their disease trajectories on currently available treatments, and reference forthcoming clinical trials.</p><p><strong>Conclusion: </strong>Clinical impact or potential implications. Response to immunosuppression and antifibrotic therapy is variable in patients with connective tissue disease-related fibrosing interstitial lung disease. Data from prospective clinical trials and longitudinal registry studies will conceivably provide additional insight into improving care for these patients.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"17 ","pages":"e187430642306150"},"PeriodicalIF":0.0,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71427649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Flexible Bronchoscopy using Biopsy Forceps as the Initial Attempt for Headscarf Pin Aspiration Extraction. 使用活检钳进行柔性支气管镜检查作为头巾针抽吸的初步尝试
Q3 Medicine Pub Date : 2023-08-07 eCollection Date: 2023-01-01 DOI: 10.2174/18743064-v17-e230718-2023-5
Mia Elhidsi, Dicky Soehardiman, Wahju Aniwidyaningsih, Mochamad Fahmi Alatas, Ginanjar Arum Desianti, Prasenohadi Pradono

Introduction: Flexible bronchoscopy is a less invasive procedure for extracting foreign bodies from the airways. However, studies on the extraction of headscarf pins are still very limited to determine the efficacy and safety of headscarf pin extraction using flexible bronchoscopy with biopsy forceps.

Methods: This retrospective study was conducted at Persahabatan Hospital, Jakarta, Indonesia, on patients who had been treated in this hospital for headscarf pin extraction between January 2013 and February 2023. Fibreoptic bronchoscopy was performed under general anaesthesia. The pin was removed using Radial Jaw 4 mm single-use pulmonary biopsy forceps. The impacted sharp tip of the pin was freed first, and the proximal part of the pin body was gripped using biopsy forceps. Once a firm hold of the sharp end or the proximal part of the pin was secured, the bronchoscope and forceps were both slowly withdrawn under direct vision.

Results: Thirty-two cases with headscarf pin aspiration were managed by fibreoptic bronchoscopy. A total of 12 patients (37.5%) came without any respiratory complaints; however, an equal number complained of cough and 6 cases (18.7%) of haemoptysis. All the cases in which the pins were visible in the airway were found with the round head down and the sharp tip oriented superiorly in the airway and impacted in the mucosa. Fibreoptic bronchoscopy extraction succeeded in 31 cases (96.8%). Only one case was converted to surgery. There were no major complications.

Conclusion: Fibreoptic bronchoscopy with biopsy forceps under general anaesthesia is safe and effective for the removal of headscarf pin aspiration.

柔性支气管镜检查是一种从气道中取出异物的微创手术。然而,关于提取头针的研究仍然非常有限,无法确定使用带活检钳的柔性支气管镜进行头针提取的有效性和安全性。这项回顾性研究在印度尼西亚雅加达Persahabatan医院进行,对象是2013年1月至2023年2月期间在该医院接受头巾拔针治疗的患者。纤维支气管镜检查是在全身麻醉下进行的。使用径向钳口4mm一次性肺部活检钳取出针。首先释放受冲击的针头尖端,并使用活检钳夹住针头主体的近端。一旦牢牢抓住针头的尖端或近端,支气管镜和镊子都会在直视下慢慢取出。采用纤维支气管镜检查对32例头针抽吸患者进行了治疗。共有12名患者(37.5%)没有任何呼吸道疾病;然而,同样数量的患者抱怨咳嗽和6例(18.7%)咯血。所有在气道中可见钉的病例都是圆形头部朝下,尖锐尖端在气道中向上,并撞击在粘膜中。纤维支气管镜取出成功31例(96.8%),只有1例转为手术。没有出现重大并发症。在全身麻醉下用活检钳进行纤维支气管镜检查是安全有效的去除头针抽吸的方法。
{"title":"Role of Flexible Bronchoscopy using Biopsy Forceps as the Initial Attempt for Headscarf Pin Aspiration Extraction.","authors":"Mia Elhidsi,&nbsp;Dicky Soehardiman,&nbsp;Wahju Aniwidyaningsih,&nbsp;Mochamad Fahmi Alatas,&nbsp;Ginanjar Arum Desianti,&nbsp;Prasenohadi Pradono","doi":"10.2174/18743064-v17-e230718-2023-5","DOIUrl":"10.2174/18743064-v17-e230718-2023-5","url":null,"abstract":"<p><strong>Introduction: </strong>Flexible bronchoscopy is a less invasive procedure for extracting foreign bodies from the airways. However, studies on the extraction of headscarf pins are still very limited to determine the efficacy and safety of headscarf pin extraction using flexible bronchoscopy with biopsy forceps.</p><p><strong>Methods: </strong>This retrospective study was conducted at Persahabatan Hospital, Jakarta, Indonesia, on patients who had been treated in this hospital for headscarf pin extraction between January 2013 and February 2023. Fibreoptic bronchoscopy was performed under general anaesthesia. The pin was removed using Radial Jaw 4 mm single-use pulmonary biopsy forceps. The impacted sharp tip of the pin was freed first, and the proximal part of the pin body was gripped using biopsy forceps. Once a firm hold of the sharp end or the proximal part of the pin was secured, the bronchoscope and forceps were both slowly withdrawn under direct vision.</p><p><strong>Results: </strong>Thirty-two cases with headscarf pin aspiration were managed by fibreoptic bronchoscopy. A total of 12 patients (37.5%) came without any respiratory complaints; however, an equal number complained of cough and 6 cases (18.7%) of haemoptysis. All the cases in which the pins were visible in the airway were found with the round head down and the sharp tip oriented superiorly in the airway and impacted in the mucosa. Fibreoptic bronchoscopy extraction succeeded in 31 cases (96.8%). Only one case was converted to surgery. There were no major complications.</p><p><strong>Conclusion: </strong>Fibreoptic bronchoscopy with biopsy forceps under general anaesthesia is safe and effective for the removal of headscarf pin aspiration.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":" ","pages":"e187430642306220"},"PeriodicalIF":0.0,"publicationDate":"2023-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49262365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Open Respiratory Medicine Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1